Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 As Monotherapy and in Combination in Patients with Advanced Haematological Malignancies.

Next Previous
Search
Trial Profile

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 As Monotherapy and in Combination in Patients with Advanced Haematological Malignancies.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Inobrodib (Primary) ; Pomalidomide (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Richter's syndrome; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors CellCentric

    • Most Recent Events

    • 07 Mar 2025 Planned End Date changed from 30 Jun 2025 to 31 Mar 2027.
    • 07 Mar 2025 Planned primary completion date changed from 30 Jun 2025 to 31 Mar 2027.
    • 06 Nov 2024 According to CellCentric Media release, new safety and efficacy data on inobrodib from phase 2 trials for patients with relapsed refractory multiple myeloma (RRMM), will be presented in an oral presentation on its groundbreaking, oral drug, inobrodib, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, on Monday, December 9th, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top